KMT2A Inhibitors
1 drugsAbout KMT2A
KMT2A is a histone methyltransferase involved in regulating gene expression through chromatin modification. It plays a crucial role in hematopoiesis and development.
Currently, there is no genetic evidence available for KMT2A as a therapeutic target. However, its role in cancer development makes it an attractive target.
KMT2A is targeted by one approved drug, KOMZIFTI, a small molecule developed by KURA Oncology for oncology indications. KOMZIFTI was first approved in 2025.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 81% attractiveness score.
- White space opportunity in Mixed Lineage Leukemia Gene Mutation with only 1 trials.
Top KMT2A Drugs
KURA Oncology is the only company with an approved drug targeting KMT2A.
Low competition suggests a high barrier to entry or untapped market potential.
KMT2A Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KMT2A, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs represents a whitespace opportunity.
KMT2A Clinical Trials 15 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 0 | 0 | 12 | - |
| Phase 2 | 2 | 0 | 0 | 2 | - |
| Phase 3 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KMT2A Drug Approval Timeline (2025 - 2025)
The first drug targeting KMT2A was approved in 2025.
Recent approval indicates growing interest, but also early stage market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (10 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 18 clinical trials targeting KMT2A.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities